Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.
R J Kurlander, J Hall
R J Kurlander, J Hall
Published June 1, 1986
Citation Information: J Clin Invest. 1986;77(6):2010-2018. https://doi.org/10.1172/JCI112530.
View: Text | PDF
Research Article Article has an altmetric score of 3

Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice.

  • Text
  • PDF
Abstract

Fc-receptor-mediated clearance and nonspecific phagocytic clearance were assessed after the infusion of monomeric human IgG, heat-aggregated human IgG, and a monoclonal anti-mouse macrophage FcII receptor antibody (2.4G2) into normal mice. Each agent blocked Fc-receptor function in vivo, but 2.4G2 was much more potent per microgram than the other agents. Monomeric IgG in blocking doses did not affect other aspects of immune function. In contrast, aggregated IgG, and to a lesser extent, 2.4G2 reduced serum complement levels. In addition, these agents also caused moderate reductions in nonspecific phagocytic function. Monoclonal anti-mouse macrophage C3bi receptor antibody (Mac-1), another monoclonal antibody which binds to macrophage CR3 receptors without interfering with Fc-receptor function, also reduced serum complement and inhibited nonspecific phagocytic function. Complement depletion alone (produced by infusion of cobra venom factor) could not account for the observed changes in Fc receptor or nonspecific phagocytic function. We conclude that both monomeric IgG and anti-Fc-receptor antibodies can markedly inhibit Fc-receptor function in vivo; however, the pattern of physiologic changes produced by these agents differs.

Authors

R J Kurlander, J Hall

×

Total citations by year

Year: 2024 2023 2021 2020 2017 2015 2014 2013 2010 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1995 1994 1993 1992 1991 1990 1989 1988 1987 Total
Citations: 1 1 2 2 1 1 1 1 1 3 1 2 1 2 2 2 1 1 2 3 1 1 2 2 2 2 5 2 4 52
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (52)

Title and authors Publication Year
Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery.
Zelepukin IV, Shevchenko KG, Deyev SM
Nature Communications 2024
Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical Update
Mohiuddin A, Mondal S
Infectious Disorders Drug Targets 2023
Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
A Hasan, E Al-Ozairi, Z Al-Baqsumi, R Ahmad, F Al-Mulla
ImmunoTargets and Therapy 2021
COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
N Tripathi, N Tripathi, MK Goshisht
Molecular Diversity 2021
Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
Y Fu, Y Cheng, Y Wu
Virologica Sinica 2020
SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions
P Asrani, I Hassan
Molecular and Cellular Biochemistry 2020
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
SP Arlauckas, CS Garris, RH Kohler, M Kitaoka, MF Cuccarese, KS Yang, MA Miller, JC Carlson, GJ Freeman, RM Anthony, R Weissleder, MJ Pittet
Science Translational Medicine 2017
A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects: Ter119 Fc DOMAIN IN MURINE ITP TREATMENT
X Yu, M Menard, G Seabright, M Crispin, AH Lazarus
Transfusion 2015
FCGR2A rs1801274 polymorphism is associated with risk of childhood-onset idiopathic (immune) thrombocytopenic purpura: Evidence from a meta-analysis
D Wang, SL Hu, XL Cheng, JY Yang
Thrombosis Research 2014
FcγRIIa and FcγRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome
A Papagianni, M Economou, A Tragiannidis, E Karatza, F Samarah, N Gombakis, F Athanassiadou-Piperopoulou, N Vavatsi–Christaki, M Athanassiou-Metaxa
Blood Coagulation & Fibrinolysis 2013
ANTI-MORPHINE ANTIBODY CONTRIBUTES TO THE DEVELOPMENT OF MORPHINE TOLERANCE IN RATS
H Kim, S Oh, B Sung, Y Tian, L Yang, S Wang, J Mao
Neuroscience Letters 2010
Intravenous immunoglobulin products: an update on their mechanisms of action
JW Semple, AR Crow, AH Lazarus, J Freedman, MB Garvey
ISBT Science Series 2008
The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenic Purpura: What Do We Really Know?
AR Crow, AH Lazarus
Transfusion Medicine Reviews 2008
Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy
F Eftimov, IN Schaik
Expert Opinion on Biological Therapy 2008
BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer
LL pottier, B Bendaoud, M Dueymes, C Daridon, P Youinou, Y Shoenfeld, J Pers
Journal of Clinical Immunology 2007
Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis
RP Lu, G Keilson
Journal of Clinical Apheresis 2006
Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia
AR Crow, S Song, V Siragam, AH Lazarus
Pediatric Blood & Cancer 2006
Facing the Enigma of Immunomodulatory Effects of Intravenous Immunoglobulin
T Sapir, Y Shoenfeld
Clinical Reviews in Allergy & Immunology 2005
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile
MC Dalakas
Pharmacology & Therapeutics 2004
Effets immunomodulateurs des immunoglobulines intraveineuses
P Guilpain, Y Chanseaud, MC Tamby, C Larroche, L Guillevin, SV Kaveri, MD Kazatchkine, L Mouthon
La Presse Médicale 2004
Role of Fc?? Receptors in the Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura
AR Crow, AH Lazarus
Journal of Pediatric Hematology/Oncology 2003
Mechanism of action of IVIG and anti-D in ITP
AH Lazarus, AR Crow
Transfusion and Apheresis Science 2003
Mechanism of action of IVIG in ITP
AH Lazarus
Vox Sanguinis 2002
Mechanisms of Intravenous Immunoglobulin Action in the Treatment of Autoimmune Disorders:
C Larroche, Y Chanseaud, P Garciadelapenalefebvre, L Mouthon
BioDrugs 2002
Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia
JL Teeling, T Jansen-Hendriks, TW Kuijpers, M de Haas, JG van de Winkel, CE Hack, WK Bleeker
Blood 2001
Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain
JL Arruda, S Sweitzer, MD Rutkowski, JA DeLeo
Brain Research 2000
Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
MC Dalakas
Muscle & Nerve 1999
Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis
S Pradhan, RP Gupta, S Shashank, N Pandey
Journal of the Neurological Sciences 1999
Intravenous immunoglobulin and Anti-D in Idiopathic Thrombocytopenic Purpura (ITP): Mechanisms of Action
AH Lazarus, J Freedman, JW Semple
Transfusion Science 1998
Intravenous Immunoglobulin G and Anti-D as Therapeutic Interventions in Immune Thrombocytopenic Purpura
V Blanchette, M Carcao
Transfusion Science 1998
Characterization of anti-mouse FcγRII single-chain Fv fragments derived from human phage display libraries
AM McCall, AR Amoroso, C Sautès, JD Marks, LM Weiner
Immunotechnology 1998
Fc receptors in liver sinusoidal endothelial cells in NZB/W F1 lupus mice: A histological analysis using soluble immunoglobulin G–immune complexes and a monoclonal antibody (2.4G2)
SS Ahmed, H Muro, M Nishimura, I Kosugi, Y Tsutsui, H Shirasawa
Hepatology 1995
Intravenous gammaglobulin, 2: pharmacology, clinical uses and mechanisms of action
RI Schiff
Pediatric Allergy and Immunology 1994
Immunotherapy in Rheumatoid Arthritis: A Review
C Vitali, MS Bombardieri
The International Journal of Artificial Organs 1993
Intravenous immunoglobulin induces interferon-? and interleukin-6in vivo
ZD Ling, E Yeoh, BT Webb, K Farrell, J Doucette, DS Matheson
Journal of Clinical Immunology 1993
High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis
B Tumiati, P Casoli, M Veneziani, G Rinaldi
Arthritis & Rheumatism 1992
Proposed mechanisms of action of intravenous IgG (IVIG) in autoimmune diseases
TW Jungi, UE Nydegger
Transfusion Science 1992
Elimination of soluble123I-labeled aggregates of IgG in patients with systemic lupus erythematosus. Effect of serum IgG and numbers of erythrocyte complement receptor type 1
C Halma, MR Daha, JH Evers-Schouten, LA van Es, FC Breedveld, D Blok, J Hermans, EK Pauwels
Arthritis & Rheumatism 1991
Monomeric IgG2a promotes maturation of bone-marrow macrophages and expression of the mannose receptor
S Schreiber, JS Blum, WF Stenson, RP MacDermott, PD Stahl, SL Teitelbaum, SL Perkins
Proceedings of the National Academy of Sciences 1991
Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis
ED Silverman, RM Laxer, M Greenwald, E Gelfand, A Shore, LD Stein, CM Roifman
Arthritis & Rheumatism 1990
Cellular and Molecular Mechanisms of Inflammation
JA Odin, CJ Painter, JC Unkeless
Cellular and Molecular Mechanisms of Inflammation 1990
Use of Intravenous Gammaglobulin as an Immune Replacement and an Immune Suppressant
LK Boshkov, JG Kelton
Transfusion Medicine Reviews 1989
Murine natural killer cells express functional Fc gamma receptor II encoded by the Fc gamma R alpha gene
B Perussia, MM Tutt, WQ Qiu, WA Kuziel, PW Tucker, G Trinchieri, M Bennett, JV Ravetch, V Kumar
Journal of Experimental Medicine 1989
Fcγ Receptor Recognition of IgG Ligand by Human Monocytes and Macrophages
MD Rossman, E Chen, P Chien, M Rottem, A Cprek, AD Schreiber
American journal of respiratory cell and molecular biology 1989
Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice
JC Edberg, L Tosic, RP Taylor
Clinical Immunology and Immunopathology 1989
Perspectives in Antiinfective Therapy
GG Jackson, HD Schlumberger, HJ Zeiler
1989
Biochemistry and safety of native intravenous gammaglobulin (IGIV, pH 4.25)
RS Schwartz
Journal of Clinical Apheresis 1988
Immunotherapy of infectious diseases: past, present and future
JE Pennington
Transactions of the American Clinical and Climatological Association 1988
A new intravenous immunoglobulin in adult and childhood idiopathic thrombocytopenic purpura: a review
RH Rousell
Journal of Infection 1987
Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25
RS Schwartz
The American Journal of Medicine 1987
In Vivo Administration of Antibodies Against Type I Collagen in Rat: The Specific Accumulation in Spleen
GL Idelson, VR Muzykantov, EE Chekneva, AA Shnyra, BV Shekhonin, SP Domogatsky
Collagen and Related Research 1987
Gammaglobulin for intravenous use induces an Fc γ receptor-specific decrement in phagocytosis by blood monocytes
JE Salmon, S Kapur, RP Kimberly
Clinical Immunology and Immunopathology 1987

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 46 patents
12 readers on Mendeley
See more details